Phase III SIMBA: MB09 vs Prolia — Key Efficacy, PK/PD, Safety Findings

The published SIMBA phase III article reports a randomized, double-blind comparison of MB09 (a denosumab biosimilar) versus reference denosumab (Prolia) in postmenopausal women with osteoporosis, with outcomes through 18 months and a transition period that included a single switch from reference product to biosimilar.

The authors report lumbar spine bone mineral density (BMD) efficacy alongside pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and findings from the switching interval. Follow-up includes a main treatment period through 12 months and an additional period through 18 months to describe comparability after continued treatment or switching.

The authors define the primary efficacy endpoint as percent change from baseline in lumbar spine BMD at 12 months, evaluated for therapeutic equivalence using prespecified margins of −1.45% to 1.45%. As reported, the primary analysis used a mixed model for repeated measures (MMRM) in the modified full analysis set and estimated a least-squares mean difference (MB09 vs reference) of 0.20% (95% CI, −0.51 to 0.91), which the authors state fell entirely within the equivalence bounds. They also describe sensitivity analyses for missing data and hypothetical scenarios as concordant with the primary analysis, without materially changing the interpretation. On that basis, the authors report that the study met the primary equivalence criterion for lumbar spine BMD at 12 months.

For secondary BMD endpoints at 6 and 12 months, the authors report results for lumbar spine as well as total hip and femoral neck that were consistent with the primary analysis pattern. PD assessments evaluated suppression of serum carboxy-terminal cross-linking telopeptide of type I collagen (sCTX), with the authors describing comparable suppression between groups. For PD, geometric least-squares mean (GLSM) ratios were reported with 90% confidence intervals within prespecified acceptance limits (80.00% to 125.00%) for the PD summary measures analyzed. PK assessments similarly reported comparable denosumab systemic exposure, with GLSM ratios and corresponding confidence intervals within predefined equivalence limits; 90% CIs were reported for main treatment period comparisons and 95% CIs for transition/switch period comparisons. The authors present the PD and PK findings as supportive components of the overall comparability package alongside BMD results.

Safety findings were described as broadly similar between groups based on treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs), with serious events characterized as infrequent across study periods. In immunogenicity assessments, the authors report that treatment-induced anti-drug antibodies (ADAs) were rare overall, neutralizing activity was not detected, and no treatment-induced ADAs were observed among participants who switched from reference product to MB09 during the transition period. Fracture events were described as uncommon with low event counts, and the authors present these data descriptively rather than as a powered efficacy comparison.

The article also notes European Medicines Agency approval of MB09 in 2025 and lists the brand names Izamby® and Denbrayce®, concluding that clinical similarity was observed across efficacy, PK/PD, safety, and immunogenicity, including after a single switch.

Key Takeaways:

• The study authors concluded that MB09 fell within the prespecified equivalence margins for percent change from baseline in lumbar spine BMD at 12 months versus reference denosumab.
• PD (sCTX) and PK (Cmax, AUC0–6 months, and Ctrough) assessments were reported as comparable, with ratios and confidence intervals within prespecified acceptance limits across study periods, including the transition/switch interval.
• Safety profiles were described as similar overall with low immunogenicity, including no treatment-induced ADAs observed in the switch arm; the article notes EMA approval in 2025 and the brand names Izamby®/Denbrayce®.